OverviewSuggest Edit

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

HQBoulder, US
Employee Ratings3.5

Latest Updates

Employees (est.) (Jun 2018)298(+43%)
Revenue (FY, 2018)$173.8 M(+16%)
Share Price (Jul 2019)$47.9

Key People/Management at Array BioPharma

Ron Squarer

Ron Squarer

Jason Haddock

Jason Haddock

Rogan P. Nunn

Rogan P. Nunn

Interim General Counsel
Kimberly Pope

Kimberly Pope

Senior Vice President, Human Resources
Andrew Robbins

Andrew Robbins

Nicholas Saccomano

Nicholas Saccomano

Chief Scientific Officer
Show more

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Cambridge, Chicago, Detroit and in 5 other locations
Boulder, US (HQ)
3200 Walnut St
Cambridge, US
100 Cambridgepark Dr #505
Chicago, US
Chicago, IL, USA
Detroit, US
Detroit, MI, USA
Houston, US
Houston, TX, USA
Miami, US
Miami, FL, USA
Show all (9)

Array BioPharma Financials and Metrics

Array BioPharma Revenue

Embed Graph
View revenue for all periods
Array BioPharma's revenue was reported to be $173.77 m in FY, 2018

Revenue (Q3, 2019)


Gross profit (Q3, 2019)


Gross profit margin (Q3, 2019), %


Net income (Q3, 2019)


EBIT (Q3, 2019)


Market capitalization (30-Jul-2019)


Closing stock price (30-Jul-2019)


Cash (31-Mar-2019)



Array BioPharma's current market capitalization is $10.7 b.
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Revenue growth, %


Cost of goods sold


Gross profit

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable


Prepaid Expenses



USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019



Accounts Receivable


Prepaid Expenses



USDY, 2019


-286 x


-122.5 x


0.4 x


0.2 x

Financial Leverage

1.9 x
Show all financial metrics

Array BioPharma Online and Social Media Presence

Embed Graph

Array BioPharma Company Culture

  • CEO Rating



  • Compensation



Learn more on Comparably

Array BioPharma News and Updates

Array BioPharma Inc., a Subsidiary of Pfizer Inc., Announces Effective Date of Make-Whole Fundamental Change and Fundamental Change Company Notice Relating to its 2.625% Convertible Senior Notes due 2024

BOULDER, Colo., July 30, 2019 /PRNewswire/ -- Array BioPharma Inc. ("Array") today announced that, in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2019, by and among Array, Pfizer...

Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

BOULDER, Colo., July 6, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of results from the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor, and ERBITUX®...

Thinking about trading options or stock in Array Biopharma, JPMorgan Chase, Coca-Cola, Match Group, or Netflix?

NEW YORK, June 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARRY, JPM, KO, MTCH, and NFLX. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

3 biotechs that investors should buy next after Pfizer's $11 billion deal for cancer drugmaker Array BioPharma

US drug giant Pfizer just announced that it is acquiring biotech Array BioPharma for $11.4 billion.  This latest deal points to a trend of big companies snapping up cancer-focused biotechs, with Merck buying the cancer biotech Tilos Therapeutics for up to $773 million last week. Investors should c…

Thinking about buying stock in Aurora Cannabis, Array Biopharma, Beyond Meat, Dare Bioscience, or Uniqure?

NEW YORK, June 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, ARRY, BYND, DARE, and QURE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

Array BioPharma Blogs

Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019

- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI and ERBITUX® (cetuximab) demonstrated 15.3 months median overall survival in safety lead-in

Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019

BOULDER, Colo. , Jan. 29, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019 . Ron Squarer, Chief Executive Officer, will lead the call.

Thomas Smith

Thomas Smith JorgeRendell.C… Thu, 01/17/2019 - 12:43 Thomas Smith Leerink

Paul Choi

Paul Choi JorgeRendell.C… Wed, 12/19/2018 - 17:37 Paul Choi Goldman Sachs

Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019

Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019 Content Import Tue, 10/30/2018 - 08:05 Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019 Oct 30, 2018 This release is a backfill from a News Wire …

Michael Schmidt, Ph.D.

Michael Schmidt, Ph.D. JorgeRendell.C… Tue, 09/25/2018 - 17:28 Michael Schmidt, Ph.D. Guggenheim Partners
Show more

Array BioPharma Frequently Asked Questions

  • When was Array BioPharma founded?

    Array BioPharma was founded in 1998.

  • Who are Array BioPharma key executives?

    Array BioPharma's key executives are Ron Squarer, Jason Haddock and Rogan P. Nunn.

  • How many employees does Array BioPharma have?

    Array BioPharma has 298 employees.

  • What is Array BioPharma revenue?

    Latest Array BioPharma annual revenue is $173.8 m.

  • What is Array BioPharma revenue per employee?

    Latest Array BioPharma revenue per employee is $583.1 k.

  • Who are Array BioPharma competitors?

    Competitors of Array BioPharma include Recro Gainesville, Zogenix and Durect.

  • Where is Array BioPharma headquarters?

    Array BioPharma headquarters is located at 3200 Walnut St, Boulder.

  • Where are Array BioPharma offices?

    Array BioPharma has offices in Boulder, Cambridge, Chicago, Detroit and in 5 other locations.

  • How many offices does Array BioPharma have?

    Array BioPharma has 9 offices.